Can Atopic Dermatitis Affect Children’s Growth and Bone Health?
Could eczema affect a child’s growth?
Atopic dermatitis, the most common form of eczema, can affect much more than a child’s skin. For children with moderate to severe symptoms, ongoing itching, inflamed skin and disrupted sleep can make daily life difficult for the whole family.
Some parents also worry about whether long-lasting eczema, poor sleep or medications might affect their child’s growth and bone health. Researchers are looking into these questions, but there is still much they do not know.
In the Dermatology Times Expert Perspectives series Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis, dermatologist Lisa Swanson, MD, discusses how doctors can consider these concerns when caring for children with eczema. The discussion covers uncontrolled symptoms, sleep, corticosteroid exposure and emerging research on the eczema medicine dupilumab. (Source: Dermatology Times, Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis)
Looking beyond the skin
Children with severe eczema may have persistent itching that interrupts sleep and makes it harder to manage everyday activities. These effects on daily life are well recognized. Researchers are also paying more attention to whether long-lasting symptoms could be connected to physical growth and bone development.
Growth questions may be especially relevant for children whose eczema has been poorly controlled for a long time or whose height is already near the lower end of a growth chart. Growth charts compare a child’s measurements with those of other children of the same age and sex. A percentile shows where a measurement falls within that comparison.
A child’s growth pattern can reflect many things. When considering a change in growth, doctors may look at the burden of eczema, past and current treatments, individual differences in development and overall health. Research has not identified one single reason why some children with eczema may have differences in height or bone-related measures.
In a 2025 study using the TriNetX health database, researchers looked back at records of children with eczema and compared them with records of similar children without it. Children with eczema had a 15% higher relative risk of having a height below the fifth percentile. The estimated increase ranged from 12% to 18%. This was a relative difference between groups, not a finding that 15% of all children with eczema had unusually short stature. (Source: 2025 TriNetX retrospective cohort analysis discussed in the Dermatology Times series)
Because researchers observed existing health records rather than assigning treatments or conditions, the study cannot show that eczema caused the difference in height. The findings suggest that growth is worth considering alongside symptom severity, treatment history and a child’s overall health.
How itching and sleep fit into the picture
Nighttime itching can make it difficult for a child to fall asleep or stay asleep. Repeated waking can leave children and their families tired and affect their quality of life.
Sleep is also connected to normal childhood growth. The body releases growth hormone in association with sleep, and regular sleep patterns are involved in the processes that help bones develop and renew themselves.
These connections have led researchers to ask whether better control of itching and sleep disruption might also affect growth-related outcomes. That possibility remains under investigation.
In the Expert Perspectives discussion, Swanson considers sleep and growth as parts of the broader picture of a child’s health, rather than as separate concerns. Information about nighttime itching, sleep quality and changes in daily activities can help a doctor understand how much eczema is affecting a child. Regular growth checks can also help identify changes that may need a closer look. (Source: Dermatology Times, Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis)
What researchers are studying about dupilumab and growth
Newer biologic medicines, which target specific parts of the immune system, have expanded treatment options for younger children with moderate to severe eczema. One of these medicines is dupilumab (Dupixent). Researchers are exploring whether better control of severe eczema is associated with changes in growth-related measures.
A 2026 analysis discussed in the series looked at height and bone alkaline phosphatase, or BALP, in children with severe eczema who received dupilumab. BALP is a substance in the blood associated with bone formation. The analysis was a post hoc analysis, meaning researchers examined the data after the original study was completed. (Source: 2026 post hoc analysis discussed in the Dermatology Times series)
The researchers proposed that less itching and better eczema control might improve sleep, which could in turn influence growth-related outcomes. But sleep was not directly measured in the analysis, so that explanation remains a possibility rather than a demonstrated link.
There are also limits to what the measures can tell us. A change in BALP may offer information about bone formation activity, but it does not directly measure bone density or establish better long-term bone health.
Changes in height percentiles can offer clues about a child’s growth pattern. They still need to be considered alongside the child’s age, earlier growth pattern, length of treatment and other possible influences.
Overall, the findings raise useful questions about the wider effects of controlling severe eczema. They do not establish that dupilumab directly increases bone density or makes children grow taller.
Talking about growth, sleep and treatment
For families already managing severe eczema, questions about development can add to the worry. Parents may wonder about the possible roles of ongoing inflammation, interrupted sleep or medications, including corticosteroids.
A doctor can help explain what is known, what researchers have observed and what remains uncertain. Conversations about sleep, itching, treatment history and how well eczema is controlled can provide context alongside routine growth measurements.
If a child has a persistent growth concern, their care team may consider a closer assessment and, when appropriate, work with the child’s pediatrician or another specialist. Treatment decisions, including questions about corticosteroids or biologic medicines, should be discussed with a doctor or dermatologist.
It is also important to remember that a possible link between eczema and growth does not mean every child with eczema will have growth problems. Each child’s health and development need to be considered individually, especially when eczema is severe or not well controlled.
When to contact a doctor
Talk with a child’s doctor if eczema is regularly interrupting sleep, interfering with daily life or raising concerns about growth. A doctor or dermatologist can also assess skin that is painful, bleeding, changing quickly or showing possible signs of infection.
This article is for general information and is not a substitute for advice from a health professional who knows your child.
Sources
- Dermatology Times. Expert Perspectives series: Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis, featuring Lisa Swanson, MD.
- 2025 retrospective cohort analysis using the TriNetX database, discussed in the original article.
- 2026 post hoc analysis of height and bone alkaline phosphatase in children receiving dupilumab for severe atopic dermatitis, discussed in the Dermatology Times series.